Promomed

Promomed is a Russian pharmaceutical company engaged in the development, production, research and distribution of medicines. The company's main production site is the Biochemik plant in Saransk.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Promomed balance sheet

Report period2019 2020 2021 2022 2023 2024
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Promomed cash flows

Report period2019 2020 2021 2022 2023 2024
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Promomed multipliers

Report period2019 2020 2021 2022 2023 2024
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Promomed profitability

Report period2019 2020 2021 2022 2023 2024
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Promomed assets
Promomed cash flows

Promomed dividend policy

The amount of dividends is determined based on the following ratio: Net Debt / Adj. EBITDA ≤ 1 - at least 50% of Adj. earnings; 1 < Net Debt / Adj. EBITDA ≤ 2 - at least 25% of Adj. earnings; 2 < Net Debt / Adj. EBITDA ≤ 2.5 - at least 15% of Adj. earnings. The basis for calculation is IFRS reporting.
Promomed operating results
by year
Number of periods: 1
Report period2024
Evolution index basic portfolio, percentage points
Evolution index endocrinology portfolio, percentage points
Index of evolution of oncology portfolio, percentage points
Own trademarks, things

Promomed shares

TickerNameTypeNominal valueISINPrice
PRMD:RMPromomedCommon shareRUB 1RU000A108JF7RUB 396

Promomed bonds

NameIssue sizePriceYield
PROMOMED DM 002P-01 (RUB)3,500,000 pcs.93.57%17.53%
PROMOMED DM 001P-03 (RUB)2,500,000 pcs.97.4%17.82%
PROMOMED DM 001P-01 (RUB)1,000,000 pcs.100.02%0.05%
PROMOMED DM 001P-02 (RUB)977,896 pcs.99.96%0.03%

Promomed expected events

DateTypeNoteSource
12.08.2025 10:00
Operating results
Operating results for 6 months of 2025Pictogram of promomed.ru  promomed.ru
28.08.2025 10:00
Financial results
Reporting for 1H 2025 under IFRSIPictogram of promomed.ru  promomed.ru
28.08.2025 10:00
Financial results
Financial statements for 6 months of 2025 under IFRSPictogram of promomed.ru  promomed.ru
18.11.2025 10:00
Operating results
Operating results for 9 months of 2025Pictogram of promomed.ru  promomed.ru
Share capital structure of Promomed
Promomed news
20.05.2025
Promomed's revenue in Q1 2025 increased by 86% to ₽4,485 million. The revenue growth rate is more than five times higher than that of the pharmaceutical market, which grew by 16%. The share of revenue from sales of innovative products increased to 69% from 58% a year earlier. The share of Endocrinology and Cancer portfolios in revenue for the first quarter o...
Source: {source} pictogram promomed.ru
Pictogram next
23.04.2025
Promomed's IFRS net profit for 2024 amounted to ₽2.88 billion, down 3% from ₽2.97 billion in the previous year. Revenue increased 35.4% to ₽21.45 billion compared to ₽15.84 billion a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
22.04.2025
Promomed launched Russia's first subscription program for patients receiving course drugs. It allows patients to purchase drugs at significant discounts and adhere to the prescribed therapy without interruptions in a comfortable financial mode. At the first stage, the subscription is available for four drugs: Quinsenta®, Velgia®, Enligria® and Tirsetta®.
Source: {source} pictogram promomed.ru
Pictogram next
29.03.2025
Promomed's RAS loss for 2024 amounted to ₽69.38 million, down 31.2% from ₽100.8 million in the previous year.
Source: {source} pictogram e-disclosure.ru
Pictogram next
All Promomed news
General information
Company namePromomed
Tags#biotechnology, #pharmacy, #ipo2024
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressMoskva, prospekt Mira, dom 13, stroenie 1
Mailing address129090, g. Moskva, prospekt Mira, dom 13, stroenie 1, etazh 2, pomeschenie 5
Websitepromomed.ru
Information disclosuree-disclosure.ru